


## Cephalexin (lysine)

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-B0200D   |
| <b>CAS No.:</b>           | 53950-14-4  |
| <b>Molecular Formula:</b> | C <sub>22</sub> H <sub>31</sub> N <sub>5</sub> O <sub>6</sub> S                           |
| <b>Molecular Weight:</b>  | 493.58  |
| <b>Target:</b>            | Bacterial; Antibiotic; Penicillin-binding protein (PBP)                                   |
| <b>Pathway:</b>           | Anti-infection  |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                                     |  |               |  |         |            |                 |                                    |         |   |
|-------------------------------------|--|---------------|--|---------|------------|-----------------|------------------------------------|---------|---|
| <b>Description</b>                  | Cephalexin (Cefalexin) lysine is a potent, orally active new semisynthetic cephalosporin antibiotic with a broad antibacterial spectrum. Cephalexin lysine has antibacterial activity against a wide variety of gram-positive and gram-negative bacteria. Cephalexin lysine targets penicillin-binding proteins (PBPs) to inhibit bacterial cell wall assembly. Cephalexin lysine is used for the research of pneumonia, strep throat, and bacterial endocarditis, et al <sup>[1][2]</sup> .   |               |  |         |            |                 |                                    |         |   |
| <b>IC<sub>50</sub> &amp; Target</b> | β-lactam   |               |  |         |            |                 |                                    |         |   |
| <b>In Vitro</b>                     | <p>Cephalexin lysine (10 μg/mL) disrupts polymer peptidoglycan (PG) biogenesis by inactivating enzymes called penicillin-binding proteins (PBPs)<sup>[1]</sup>.</p> <p>Cephalexin lysine inhibits a broad spectrum of gram-positive and gram-negative organisms with MIC values of 2, 2, 2, 4, 4.4 and 5.7 μg/mL for <i>Bacillus anthracis</i>, <i>Edwardsiella taFda</i>, <i>Vibrio cholera</i>, <i>Pasteurella multocida</i>, <i>Edwardsiella tarda</i>, <i>Alcaligenes sp</i> and <i>Proteus rettgeri</i>, respectively<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>   |               |  |         |            |                 |                                    |         |   |
| <b>In Vivo</b>                      | <p>Cephalexin lysine (0-50 mg/kg; p.o.; for 3.5 hours) has antibacterial activity in male Swiss-Webster mice with infected bacterial<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male Swiss-Webster mice with infected bacterial<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0-50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; for 3.5 hours</td> </tr> <tr> <td>Result:</td> <td>Had antibacterial activity against <i>Streptococcus pyogenes</i>, <i>Streptococcus pneumoniae</i>, <i>Staphylococcus aureus</i> and several gram-negative species mice.</td> </tr> </table> | Animal Model: | Male Swiss-Webster mice with infected bacterial <sup>[2]</sup> | Dosage: | 0-50 mg/kg | Administration: | Oral administration; for 3.5 hours | Result: | Had antibacterial activity against <i>Streptococcus pyogenes</i> , <i>Streptococcus pneumoniae</i> , <i>Staphylococcus aureus</i> and several gram-negative species mice. |
| Animal Model:                       | Male Swiss-Webster mice with infected bacterial <sup>[2]</sup>   |               |  |         |            |                 |                                    |         |   |
| Dosage:                             | 0-50 mg/kg   |               |  |         |            |                 |                                    |         |   |
| Administration:                     | Oral administration; for 3.5 hours   |               |  |         |            |                 |                                    |         |   |
| Result:                             | Had antibacterial activity against <i>Streptococcus pyogenes</i> , <i>Streptococcus pneumoniae</i> , <i>Staphylococcus aureus</i> and several gram-negative species mice.  |               |  |         |            |                 |                                    |         |   |

### CUSTOMER VALIDATION

- Theranostics. 2022 Jan 1;12(3):1187-1203.

- 
- Chemosphere. 2021, 131417.
  - Chemosphere. 2019 Jun;225:378-387.
  - J Med Chem. 2021 Sep 21.
  - Infect Immun. 2018 May 22;86(6). pii: e00090-18.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Cho H, et, al. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell. 2014 Dec 4;159(6):1300-11.
- [2]. Buck RE, et, al. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1977 Feb;11(2):324-30.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA